Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has issued an update.
On May 4, 2026, Pulse Biosciences reported first-quarter 2026 results and a sharpened strategic focus on electrophysiology after landmark data for its nPulse Cardiac Catheter System, including high 6- and 12-month procedural success and arrhythmia-free rates in a European feasibility study. The company began U.S. pivotal NANOPULSE-AF trial enrollment in early April 2026, accelerated its expected completion to early fourth quarter 2026, progressed the NANOCLAMP-AF surgical AF pivotal trial toward expected enrollment completion by mid-2027, and reinforced leadership with a new chief medical officer and chief operating officer.
In soft tissue ablation, Pulse Biosciences generated $0.4 million in Vybrance-related revenue, advanced benign thyroid nodule and thyroid cancer feasibility studies with encouraging volume reduction and durability data, but continued to post substantial losses as it ramped clinical investment. For the quarter ended March 31, 2026, revenue was $0.4 million against GAAP operating costs of $19.6 million and a GAAP net loss of $18.6 million, with cash and equivalents at $68.3 million—down from a year earlier—partially offset by access to an at-the-market program and a large shelf registration, while the company also granted stock options to new hires to support its expanding operations.
The most recent analyst rating on (PLSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held down primarily by weak financial performance—minimal revenue, large losses, and elevated cash burn—despite a comparatively supportive low-debt balance sheet. Technicals are constructive with the stock trading above major moving averages, and the earnings call points to strong clinical/regulatory momentum, but valuation remains challenged given ongoing unprofitability and no dividend support.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company developing its proprietary nPulse technology, which delivers nanosecond pulsed field ablation energy to non-thermally clear cells while sparing adjacent tissue. The company is focusing this platform on treating atrial fibrillation via cardiac catheter and surgical systems and on select soft tissue ablation markets, including thyroid applications, aiming to improve outcomes for patients and providers.
Average Trading Volume: 368,647
Technical Sentiment Signal: Buy
Current Market Cap: $1.42B
Find detailed analytics on PLSE stock on TipRanks’ Stock Analysis page.